Payment overview · 2025
General Payments
$4,450.06
58 reported records · 35 companies
Healthcare provider profile · identity verified
Nashat Gabrail, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · CANTON, OH · NPI 1104854751
Verified facts
What the public records show
CMS Open Payments records show Nashat Gabrail, M.D. received $4,450.06 in general payments during 2025 across 58 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 37.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 53 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Doptelet.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Lupron Depot by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ibrance by this doctor in 2024.
SOBI, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Doptelet as an associated drug or biological on 3467 records involving 2004 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Doptelet by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $1,676.39 | 37.7% | 5 | 2025 |
| SANOFI US SERVICES INC. | Unresolved — no canonical attribution shown | $1,246.50 | 28.0% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $122.84 | 2.8% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $109.67 | 2.5% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $103.47 | 2.3% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $98.43 | 2.2% | 5 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $82.70 | 1.9% | 3 | 2025 |
| AVYXA PHARMA, LLC | Unresolved — no canonical attribution shown | $79.17 | 1.8% | 1 | 2025 |
| SHORLA ONCOLOGY INC. | Unresolved — no canonical attribution shown | $64.26 | 1.4% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $59.32 | 1.3% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $58.82 | 1.3% | 3 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $55.79 | 1.2% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $50.60 | 1.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.22 | 1.1% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $44.75 | 1.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.82 | 1.0% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $43.01 | 1.0% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $41.75 | 0.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $33.33 | 0.8% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $32.00 | 0.7% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.70 | 0.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.62 | 0.7% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $29.00 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.86 | 0.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.70 | 0.6% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $27.61 | 0.6% | 1 | 2025 |
| MENARINI SILICON BIOSYSTEMS, INC. | Unresolved — no canonical attribution shown | $23.84 | 0.5% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $22.28 | 0.5% | 1 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $21.68 | 0.5% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.10 | 0.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.48 | 0.5% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $19.43 | 0.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.19 | 0.4% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $18.59 | 0.4% | 1 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $17.14 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $2,853.00 | 2 |
| Food and Beverage | $1,597.06 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $1,645.79 | 3 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $122.84 | 2 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $109.67 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $82.70 | 3 | 2025 |
Source payment records
|
|||||
| AXTLE Normalized: axtle |
Drug | AVYXA PHARMA, LLC | $79.17 | 1 | 2025 |
Source payment records
|
|||||
| DOCIVYX Normalized: docivyx |
Drug | AVYXA PHARMA, LLC | $79.17 | 1 | 2025 |
Source payment records
|
|||||
| FRINDOVYX Normalized: frindovyx |
Drug | AVYXA PHARMA, LLC | $79.17 | 1 | 2025 |
Source payment records
|
|||||
| LUTRATE DEPOT Normalized: lutrate depot |
Drug | AVYXA PHARMA, LLC | $79.17 | 1 | 2025 |
Source payment records
|
|||||
| POSFREA Normalized: posfrea |
Drug | AVYXA PHARMA, LLC | $79.17 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.89 | 4 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $67.67 | 2 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $63.11 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $55.79 | 2 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC., Genmab U.S., Inc. | $51.90 | 2 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $50.60 | 2 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $48.22 | 2 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $48.22 | 2 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $48.22 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $44.75 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $44.50 | 3 | 2025 |
Source payment records
|
|||||
| ENJAYMO Normalized: enjaymo |
Drug | RECORDATI_RARE_DISEASES_INC. | $43.01 | 2 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $41.75 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| IMKELDI Normalized: imkeldi |
Drug | SHORLA ONCOLOGY INC. | $37.63 | 1 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $35.80 | 1 | 2025 |
Source payment records
|
|||||
| ALYMSYS Normalized: alymsys |
Drug | Amneal Pharmaceuticals LLC | $35.33 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $33.33 | 1 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Scientific Affairs, LLC | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Scientific Affairs, LLC | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $29.70 | 1 | 2025 |
Source payment records
|
|||||
| LYNOZYFIC Normalized: lynozyfic |
Biological | Regeneron Healthcare Solutions, Inc. | $29.00 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| ELZONRIS Normalized: elzonris |
Drug | Stemline Therapeutics Inc. | $27.61 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SHORLA ONCOLOGY INC. | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| VPRIV Normalized: vpriv |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Cellsearch Normalized: cellsearch |
Device | MENARINI SILICON BIOSYSTEMS, INC. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| PEMRYDI RTU Normalized: pemrydi rtu |
Drug | Amneal Pharmaceuticals LLC | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| Odomzo Normalized: odomzo |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| YONSA Normalized: yonsa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Doptelet doptelet |
2025 | Doptelet | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
80 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| SOBI, INC Exact reporting entity; no affiliate inference |
2025 | Doptelet open payments reported associated product |
CMS Open Payments — General Payments 3467 supporting records · 2004 recipient NPIs · example record 1240223702 |
Doptelet · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Procrit | Epoetin Alfa | 133 | 19 |
| Zarxio | Filgrastim-Sndz | 121 | 13 |
| Xarelto | Rivaroxaban | 80 | 15 |
| Bortezomib | Bortezomib | 60 | suppressed |
| Ibrance | Palbociclib | 55 | suppressed |
| Dexamethasone | Dexamethasone | 48 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 48 | 33 |
| Imatinib Mesylate | Imatinib Mesylate | 46 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 44 | 20 |
| Lupron Depot | Leuprolide Acetate | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | 11 |
| Allopurinol | Allopurinol | 31 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Exemestane | Exemestane | 31 | suppressed |
| Prednisone | Prednisone | 30 | 14 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 30 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 12 |
| Eliquis | Apixaban | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 16 |
| Doptelet | Avatrombopag Maleate | 24 | suppressed |
| Letrozole | Letrozole | 23 | suppressed |
| Ocrevus | Ocrelizumab | 23 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Metformin Hcl | Metformin Hcl | 19 | suppressed |
| Revlimid | Lenalidomide | 18 | suppressed |
| Hydroxyurea | Hydroxyurea | 17 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Ruxience | Rituximab-Pvvr | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Inrebic | Fedratinib Dihydrochloride | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,450.06 · 58 records | Bayer Healthcare Pharmaceuticals Inc. | ALYMSYS, AXTLE, BESREMI, CABOMETYX, Cellsearch, DARZALEX, DOCIVYX, Doptelet, ELZONRIS, ENJAYMO, EPKINLY, Enhertu, FRINDOVYX, FRUZAQLA, FUROSCIX, HYQVIA, IMFINZI, IMKELDI, JAYPIRCA, JEMPERLI, LUTRATE DEPOT, LYNOZYFIC, Lenvima, NUCALA, Nubeqa, OCTAGAM IMMUNE GLOBULIN (HUMAN), OGSIVEO, ORGOVYX, Odomzo, PEMGARDA, PEMRYDI RTU, PLUVICTO, POSFREA, POTELIGEO, PYRUKYND, RYBREVANT, SARCLISA, Stivarga, TALVEY, TALZENNA, TECVAYLI, ULTOMIRIS, VEGZELMA, VERZENIO, VPRIV, VYEPTI, Vitrakvi, Vonjo, XT CDX, XTANDI, Xofigo, YONSA, ZEJULA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Doptelet play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error